Neoadjuvant and Adjuvant Nivolumab and Lirilumab in Patients with Recurrent, Resectable Squamous Cell Carcinoma of the Head and Neck.

Glenn J HannaAnne ONeillKee-Young ShinKristine WongVickie Y JoCharles T QuinnJennifer M CutlerMichelle FlynnPatrick H LizotteDonald J AnninoLaura A GoguenJason I KassEleni M RettigRosh K V SethiJochen H LorchJonathan D SchoenfeldDanielle N MargalitRoy B TishlerPeter C EverettAnupam M DesaiMegan E CavanaughCloud P PaweletzAnn Marie EgloffRavindra UppaluriRobert I Haddad

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2021)

(Neo)adjuvant N + L was well tolerated, with a 43% pathologic response rate. We observed favorable DFS and excellent 2-year OS among high-risk, previously treated patients exhibiting a pathologic response. Further evaluation of this strategy is warranted.

Keyphrases

locally advanced
squamous cell carcinoma
neoadjuvant chemotherapy
rectal cancer
end stage renal disease
early stage
newly diagnosed
ejection fraction
chronic kidney disease
radiation therapy
lymph node
peritoneal dialysis
prognostic factors
lymph node metastasis
patient reported outcomes